Endometrial adenocarcinoma with mutations in POLE, TP53 genes and microsatellite instability

Chernev A.A.

Medical Institute named after Berezin Sergey

ORCID: 0009-0003-7315-0878

Kravtcova E.D.

Medical Institute named after Berezin Sergey

ORCID: 0000-0003-1920-9798

Nechushkina V.M.

Eurasian Federation of Oncology;
Privolzhsky Research Medical University

ORCID: 0000-0002-1855-9692

Abasov R.H.

Medical Institute named after Berezin Sergey;
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology

ORCID: 0000-0001-9179-8430

Filipenko M.L.

Institute of Chemical Biology and Fundamental Medicine

ORCID: 0000-0002-8950-5368

Druy A.E.

Medical Institute named after Berezin Sergey;
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology

ORCID: 0000-0003-1308-8622

Raskin G.A.

Medical Institute named after Berezin Sergey;
St. Petersburg State University

ORCID: 0000-0002-7522-6552

Endometrial adenocarcinoma with mutations in POLE, TP53 genes and microsatellite instability

Authors:

Chernev A.A., Kravtcova E.D., Nechushkina V.M., Abasov R.H., Filipenko M.L., Druy A.E., Raskin G.A.

More about the authors

Journal: Russian Journal of Archive of Pathology. 2024;86(6): 58‑62

DOI: 10.17116/patol20248606158

Downloaded: 4

Contact the author

Table of contents

To cite this article:

Chernev AA, Kravtcova ED, Nechushkina VM, Abasov RH, Filipenko ML, Druy AE, Raskin GA. Endometrial adenocarcinoma with mutations in POLE, TP53 genes and microsatellite instability. Russian Journal of Archive of Pathology. 2024;86(6):58‑62. (In Russ.)
https://doi.org/10.17116/patol20248606158

Подписка 2025-2 (Russian Journal of Archive of Pathology)

Close metadata

Recommended articles:

Long-term follow-up of a patient with disseminated endometrial adenocarcinoma and cerebral metastases. P.A. Herzen Journal of Oncology. 2024;(3):63-67

Specific antitumour immunity and mechanisms of tumour escape from immunological surveillance. P.A. Herzen Journal of Oncology. 2024;(6):70-77

Prognosis and prevention of recurrent and atypical endometrial hyperplasia in women of reproductive age. Russian Bulletin of Obstetrician-Gynecologist. 2024;(6):59-65

Live birth rates after conservative treatment of atypical hyperplasia and initial endometrial cancer. Russian Journal of Human Reproduction. 2025;(1):78-85

The molecular classification of endometrial cancer developed by The Cancer Genome Atlas project (TCGA, 2013) is currently actively used in gynecological oncology. According to it, endometrial carcinoma is divided into four molecular subtypes: POLE-mutated, MMR deficient (dMMR), TP53-aberrant and unspecified. Endometrial cancer samples belonging to the dMMR and POLE-mutant types are characterized by specific genetic profiles reflecting the hyper- and ultramutant phenotypes of the tumor. At the same time POLE-mutated endometrial carcinomas recur rarely and exhibit the excellent prognosis. Here we report the rare case of 65 y.o. female patient with endometrioid carcinoma sharing immunohistochemical and molecular features of TP53-aberrant, MMR deficient and POLE-mutated subtypes.

Keywords:

endometrial carcinoma

POLE

TP53

microsatellite instability

Authors:

Chernev A.A.

Medical Institute named after Berezin Sergey

ORCID: 0009-0003-7315-0878

Kravtcova E.D.

Medical Institute named after Berezin Sergey

ORCID: 0000-0003-1920-9798

Nechushkina V.M.

Eurasian Federation of Oncology;
Privolzhsky Research Medical University

ORCID: 0000-0002-1855-9692

Abasov R.H.

Medical Institute named after Berezin Sergey;
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology

ORCID: 0000-0001-9179-8430

Filipenko M.L.

Institute of Chemical Biology and Fundamental Medicine

ORCID: 0000-0002-8950-5368

Druy A.E.

Medical Institute named after Berezin Sergey;
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology

ORCID: 0000-0003-1308-8622

Raskin G.A.

Medical Institute named after Berezin Sergey;
St. Petersburg State University

ORCID: 0000-0002-7522-6552

Received:

27.05.2024

Accepted:

26.06.2024

List of references:

Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983;15(1):10-17. https://doi.org/10.1016/0090-8258(83)90111-7
Cancer Genome Atlas Research Network. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497(7447):67-73. https://doi.org/10.1038/nature12113
Imboden S, Nastic D, Ghaderi M, Rydberg F. Rau TT. Mueller MD, Epstein E, Carlson JW. Phenotype of POLE-mutated endometrial cancer. PLoS One. 2019;14(3):e0214318. https://doi.org/10.1371/journal.pone.0214318
Li MM, Datto M, Duncavage EJ, Kulkarni S, Lindeman NI, Roy S, Tsimberidou AM, Vnencak-Jones C, Wolff DJ, Younes A, et al. Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. J Mol Diagn. 2017;19(1):4-23. https://doi.org/10.1016/j.jmoldx.2016.10.002
León-Castillo A, Gilvazquez E, Nout R, Smit VT, McAlpine JN, McConechy M, Kommoss S, Brucker SY, Carlson JW, Epstein E, et al. Clinicopathological and molecular characterisation of ‘multiple-classifier’ endometrial carcinomas. J Pathol. 2020;250(3): 312-322. https://doi.org/10.1002/path.5373
Church DN, Stelloo E, Nout RA, Valtcheva N, Depreeuw J, ter Haar N, Noske A, Amant F, Tomlinson IP, Wild PJ, et al. Prognostic significance of POLE proofreading mutations in endometrial cancer. J Natl Cancer Inst. 2014;107(1):402. https://doi.org/10.1093/jnci/dju402
Concin N, Matias-Guiu X, Vergote I, Cibula D, Mirza MR, Marnitz S, Ledermann J, Bosse T, Chargari C, Fagotti A, et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer. 2021;31(1):12-39. https://doi.org/10.1136/ijgc-2020-002230

Close metadata